TMS in the Treatment of the Sequelae of Closed Brain Injury

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT00531258

Recruitment Status : Unknown

Verified May 2008 by Bayside Health.
Recruitment status was: Recruiting

First Posted : September 18, 2007

Last Update Posted : May 9, 2008

Sponsor:

Information provided by:

Bayside Health

Study Description

Brief Summary:

Depression is very common in people who have experienced a traumatic brain injury. Few treatments have been found to be effective in treating depression in this situation. We intend to investigate the effectiveness of a form of brain stimulation, transcranial magnetic stimulation, which has been found to be effective in treating depression in people who have not undergone a brain injury. By evaluating new methods of treating depression in this population, we hope to increase the options available for treating people in this difficult situation. Furthermore, problems with aspects of thinking are also commonly present post brain injury, as in some individuals with depression. Various brain stimulation techniques, including transcranial magnetic stimulation (TMS) have been shown to have a positive effect on cognition. We also intend to investigate whether a therapeutic effect on cognitive deficits is present following TMS, in addition to any effects on depression. New treatment protocols will be developed, and understanding of the pathology and treatment of post traumatic brain injury depression will be enhanced.

Condition or disease	Intervention/treatment	Phase
Depression Closed Head Injury	Device: rTMS Device: Sham rTMS	Phase 2

Detailed Description:

It is plausible to propose that the same treatment paradigm may result in an improvement in mood and cognition with the possibility that these changes will be self reinforcing resulting in enhanced quality of life and reduced service demands.

The proposal for the use of rTMS in the treatment of post TBI depression is also supported by aetiological models. In particular, rTMS would seem to have considerable potential to improve pathophysiological changes relevant to the treatment of post TBI depression and cognitive dysfunction. Early models of the mechanism of action of rTMS treatment in depression were based on the observation that rTMS is able to produce localised changes in cortical activity [7]. The standard treatment paradigm generally has been found to produce an increase in local prefrontal cortical excitability. However, more recently there has been an increased understanding that rTMS modulates distal brain regions as well and potentially the strength of connections between brain regions. It has been proposed that its therapeutic effects in non TBI-related depression occur through modulation of dorsal frontal - subcortical limbic connectivity and potentially the actual integrity and strength of connections between these regions. If this is the case, altering cortical - cortical or cortical - subcortical connectivity may lead to therapeutic benefits in post TBI depression due to likely involvement of white matter changes in the development of TBI related mood disorder.

Aims/Objectives/Hypothesis/es Primary Aim: To assess the effectiveness of rTMS in treating depression post traumatic brain injury.

Secondary Aim: To gain preliminary data as to the possible effectiveness of rTMS in treating cognitive deficits post traumatic brain injury.

Hypothesis 1: Active bilateral sequential rTMS will lead to an improvement in the symptoms of post TBI depression, as measured by MADRS scores, when compared to sham treatment Hypothesis 2: Active bilateral sequential rTMS will lead to an improvement in cognitive executive functioning in individuals post TBI, when compared to sham treatment Hypothesis 3: Active bilateral sequential rTMS will lead to an improvement in life satisfaction and level of functioning in individuals post TBI, when compared to sham treatment.

Methodology Experimental Design and Randomisation Procedures The study has been designed to allow the reporting of results in a manner consistent with the international CONSORT guidelines. The study will involve a 4-week (20 session) randomized double-blind clinical trial with 2 treatment arms conducted at the Alfred Psychiatry Research Centre in Melbourne. Randomization will occur via the generation of a computer number sequence. Subjects will be randomized immediately prior to the commencement of the first treatment session, after the measurement of bilateral resting motor thresholds with standard means.

The main study phase (phase 1) will involve the 4 week randomized controlled trial conducted under strict double-blind conditions. Fidelity of the blinding process will be assessed at the end of this period with patients and raters. Phase 2 will involve the provision of open label treatment to patients who received sham treatment and wish to receive 'active' rTMS.

Responders to active treatment from phase 1 or 2 (defined as a 50% reduction in MADRS scores persisting for 1 week following the end of acute treatment) will enter phase 3, a 6 month maintenance phase. During this time, a single rTMS treatment session will be provided every week for 2 months and then every 2 weeks for 4 months. Acute treatment for up to 4 weeks will be reinstated if there is a persistent (2 week) increase in MADRS score of >25%.

Study Design


Study Type :	Interventional (Clinical Trial)
Estimated Enrollment :	50 participants
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Masking:	Double (Participant, Outcomes Assessor)
Primary Purpose:	Treatment
Official Title:	The Use of Non Invasive Brain Stimulation in the Treatment of the Sequelae of Closed Brain Injury
Study Start Date :	October 2007
Estimated Primary Completion Date :	December 2009
Estimated Study Completion Date :	December 2010

Resource links provided by the National Library of Medicine

Genetics Home Reference related topics: Depression

U.S. FDA Resources

Arms and Interventions

Arm	Intervention/treatment
Active Comparator: 1	Device: rTMS Bilateral rTMS
Placebo Comparator: 2	Device: Sham rTMS sham rTMS

Outcome Measures

Primary Outcome Measures :

Depression Symptom Severity [ Time Frame: 4 weeks ]

Secondary Outcome Measures :

Cognitive Tasks [ Time Frame: 4 Weeks ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:	18 Years to 60 Years (Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion criteria:

Be aged 18-60 and have capacity to consent
Currently meet DSM-IV criteria for a diagnosis of major depressive disorder (expect for the exclusion of causality by a general medical condition referring to the TBI) and have the persistence of depressive symptoms for at least one month at sufficient severity to warrant the diagnosis.
Have experienced a closed head injury of mild to moderate severity (Glasgow coma scale score (GCS) of greater than 8), preceding their depression, and are at least 3 months post injury. The injury must not have involved specific direct damage to either frontal lobe.
Have a Montgomery Asberg Rating Scale Score of > 20 (moderate - severe depression). Including only a more severely ill group of subjects limits the placebo response rate.
Have had no increase or initiation of new antidepressant (or other psychoactive) therapy in the 4 weeks prior to enrolment.

Exclusion Criteria:

Patients who have an unstable medical condition, neurological disorder or any history of a seizure disorder or are currently pregnant or lactating.
Patients who have experienced clear structural damage to the left or right dorsolateral prefrontal cortex as documented on MRI scan
Have a current DSM IV diagnosis of alcohol or substance dependence disorder.

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00531258

Contacts


Contact: Paul B Fitzgerald, MBBS, MPM, FRANZCP, PhD	+61 3 9076 6552 ext 66552	p.fitzgerald@alfred.org.au
Contact: Kate E Hoy, BBNSc (Hons)	+ 61 3 9076 5030 ext 65030	k.hoy@alfred.org.au

Locations


Australia, Victoria
Alfred Psychiatry Research Centre	Recruiting
Prahran, Victoria, Australia, 3181
Principal Investigator: Paul B Fitzgerald, MBBS, FRANZCP, PhD

Sponsors and Collaborators

Bayside Health

Investigators


Principal Investigator:	Paul B Fitzgerald, MBBS, FRANZCP, PhD	Alfred Psychiatry Research Centre

More Information


Responsible Party:	Professor Paul Fitzgerald, Alfred Psychiatry Research Centre
ClinicalTrials.gov Identifier:	NCT00531258 History of Changes
Other Study ID Numbers:	011007
First Posted:	September 18, 2007 Key Record Dates
Last Update Posted:	May 9, 2008
Last Verified:	May 2008

Keywords provided by Bayside Health:


Depression TBI TMS Major Depression resulting from a mild to moderate closed head injury

Additional relevant MeSH terms:


Wounds and Injuries Depression Brain Injuries Craniocerebral Trauma Head Injuries, Closed Behavioral Symptoms	Brain Diseases Central Nervous System Diseases Nervous System Diseases Trauma, Nervous System Wounds, Nonpenetrating

To Top